IL-11 is known to promote the development of colorectal cancer in humans and mice, but when and where IL-11 is expressed during cancer development is unknown.
"To address these questions experimentally, we generated reporter mice that express the green fluorescent protein (EGFP) gene in interleukin 11 (IL-11)-producing (IL11 ) cells in vivo.
We found IL-11 cells in the colons of this murine colitis-associated colorectal cancer model," said Dr Nishina, the lead author of a study published in Nature Communications.
"The IL-11 cells were absent from the colon under normal conditions but rapidly appeared in the tissues of mice with colitis and colorectal cancer."
In the study, Dr Nishina and colleagues characterised the IL-11 cells by flow cytometry and found that most IL-11 cells express stromal cell surface markers, such as Thy1, podoplanin, and Sca-1, suggesting that IL-11 cells are stromal fibroblasts. RNA-seq analysis revealed that the expression of approximately 350 genes was elevated in IL-11 fibroblasts compared to IL-11- fibroblasts.
These genes were also elevated in murine and human colorectal cancer tissues in vivo. IL-11 released from IL-11 cells induced activation signals in nearby tumour cells and fibroblasts in a paracrine or autocrine manner.
Thus, IL-11 fibroblasts and tumour cells constitute the tumour microenvironment that supports tumour growth.
"We looked at human cancer databases and found that elevated expression of genes enriched in IL-11 fibroblasts correlates with short duration of disease-free survival.
We think IL-11 fibroblasts can be new therapeutic targets for treating human colorectal cancer," said Prof. Nakano, the senior author of the study.
These results were published in Nature Communications.
This research was conducted in collaboration with Associate Professors Nobuhiro Tada and Hideo Yagita of Juntendo University, Professor Masato Ohtsuka of Tokai University, Professors Koji Matsushima and Chiharu Nishiyama of Tokyo University of Science, Professor Masanobu Oshima of Kanazawa University, and Naohiro Inohara of Michigan University.
Source: Toho University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.